NewsBenzingaNeurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B Benzinga 2026.11.02 22:01 (GMT+0) Open on Benzinga Other news US ADP employment change for week ending Oct. 31: 23,750, previous 19,750 Tether Capital Makes Strategic Investment in Stables to Expand USDT Cross-Border Payment Infrastructure in Asia and Middle East US SOL spot ETFs record single-day total net inflow of $11.684 million Is Wall Street Bullish or Bearish on Zimmer Biomet Stock? Clorox Stock Outlook: Is Wall Street Bullish or Bearish? Bitcoin spot ETFs see $7.99M total net inflow yesterday, led by BlackRock's IBIT with $76.5M
Tether Capital Makes Strategic Investment in Stables to Expand USDT Cross-Border Payment Infrastructure in Asia and Middle East